Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Epigenetic dysregulation is a hallmark of many cancers, often involving alterations in epigenetic machinery.
• First-generation epigenetic therapies have paved the way for newer, more selective agents.
• Targeting mutated or translocated proteins involved in cancer epigenetics is a key focus.

Purpose of the Study:

• To review epigenetic modulatory agents in current clinical development.
• To discuss the opportunities and challenges associated with their clinical advancement.
• To provide an overview of ongoing drug discovery efforts for novel and existing epigenetic targets.

Main Methods:

• Literature review of epigenetic modulatory agents in clinical development.
• Analysis of clinical trial data and outcomes for epigenetic therapies.
• Examination of drug discovery strategies for epigenetic targets in cancer.

Main Results:

• A new generation of selective epigenetic drugs targeting cancer-specific protein alterations are in clinical development.
• Clinical trial results for these agents are beginning to emerge, demonstrating their potential.
• Drug discovery continues to identify novel and existing epigenetic targets for therapeutic intervention.

Conclusions:

• Selective epigenetic therapies targeting mutated proteins represent a promising advancement in cancer treatment.
• Further research and development are crucial to overcome challenges and maximize the potential of these agents.
• Ongoing drug discovery efforts are expanding the landscape of epigenetic targets for cancer therapy.